File(s) stored somewhere else
Please note: Linked content is NOT stored on La Trobe and we can't guarantee its availability, quality, security or accept any liability.
Targeting triple-negative breast cancers with the Smac-mimetic birinapant
journal contributionposted on 11.12.2020, 00:36 by N Lalaoui, Delphine MerinoDelphine Merino, G Giner, F Vaillant, D Chau, L Liu, T Kratina, Bhupinder PalBhupinder Pal, JR Whittle, Nima Etemadi, Jean BertheletJean Berthelet, J Gräsel, C Hall, ME Ritchie, Matthias ErnstMatthias Ernst, GK Smyth, David Vaux, JE Visvader, GJ Lindeman, John SilkeJohn Silke
© 2020, The Author(s), under exclusive licence to ADMC Associazione Differenziamento e Morte Cellulare. Smac mimetics target inhibitor of apoptosis (IAP) proteins, thereby suppressing their function to facilitate tumor cell death. Here we have evaluated the efficacy of the preclinical Smac-mimetic compound A and the clinical lead birinapant on breast cancer cells. Both exhibited potent in vitro activity in triple-negative breast cancer (TNBC) cells, including those from patient-derived xenograft (PDX) models. Birinapant was further studied using in vivo PDX models of TNBC and estrogen receptor-positive (ER+) breast cancer. Birinapant exhibited single agent activity in all TNBC PDX models and augmented response to docetaxel, the latter through induction of TNF. Transcriptomic analysis of TCGA datasets revealed that genes encoding mediators of Smac-mimetic-induced cell death were expressed at higher levels in TNBC compared with ER+ breast cancer, resulting in a molecular signature associated with responsiveness to Smac mimetics. In addition, the cell death complex was preferentially formed in TNBCs versus ER+ cells in response to Smac mimetics. Taken together, our findings provide a rationale for prospectively selecting patients whose breast tumors contain a competent death receptor signaling pathway for the further evaluation of birinapant in the clinic.